Remibrutinib Improves Quality of Life in Urticaria

TOPLINERemibrutinib demonstrated early improvements in disease symptoms, sleep, and daily functioning in patients with chronic spontaneous urticaria (CSU) who continued to have symptoms despite receiving second-generation H1-antihistamines (sgH1-AHs).METHODOLOGYResearchers conducted a pooled analysis of two phase 3 trials to evaluate the efficacy of remibrutinib — an oral, highly selective Bruton tyrosine kinase inhibitor — in adults with CSU who remained symptomatic despite treatment with sgH1-AHs.A total of 912 patients were randomly assigned to receive either oral remibrutinib 25 mg twice daily (n = 606; mean age, 43.3 years; 66.5% women) or placebo (n = 306; mean age, 43.7 years; 66.7% women) for 24 weeks, followed by an open-label treatment period of 28 weeks during which all…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.